GlassScriptPhysician profile
Monica Agarwal
NPI 1578850541
$2,495.09
in general payments reported to CMS, 2019-2025
27 companies · $1,034 in 2025
The $1,034 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $135 · 2020: $45.98 · 2022: $44.94 · 2023: $733 · 2024: $503 · 2025: $1,034.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,269.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,269.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $433.98 | 2023-2025 | Vraylar, Qulipta, Ubrelvy |
| Lilly USA, LLC | $262.46 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $197.58 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $183.35 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $142.04 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $140.71 | 2019-2024 | Jardiance |
| Abbott Laboratories | $133.06 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Axsome Therapeutics, INC. | $122.29 | 2023-2025 | Auvelity |
| Lundbeck LLC | $102.32 | 2023-2025 | Vyepti, Rexulti |
| Exact Sciences Corporation | $99.08 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $94.51 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Astellas Pharma US INC | $76.99 | 2024-2025 | Veozah |
| Sanofi-Aventis U.S. LLC | $76.34 | 2022-2023 | |
| Corcept Therapeutics | $53.07 | 2025 | Korlym |
| Neurocrine Biosciences, INC. | $43.18 | 2023-2024 | Ingrezza |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $42.28 | 2020-2024 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $37.16 | 2025 | Xifaxan |
| Ucb, INC. | $34.94 | 2019 | |
| Novartis Pharmaceuticals Corporation | $34.17 | 2025 | |
| Phathom Pharmaceuticals, INC. | $29.97 | 2023-2025 | Voquezna |
| Amgen INC. | $28.32 | 2024 | Krystexxa |
| Daiichi Sankyo INC. | $27.91 | 2023 | Injectafer |
| Sumitomo Pharma America, INC. | $22.58 | 2024 | Gemtesa |
| Idorsia Pharmaceuticals US INC | $22.19 | 2024 | Quviviq |
| Acadia Pharmaceuticals INC | $20.00 | 2019 | |
| Horizon Therapeutics Plc | $19.84 | 2023 | Krystexxa |
| Regeneron Healthcare Solutions, INC. | $14.77 | 2023 | Evkeeza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monica Agarwal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.